Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients

BACKGROUND: The treatment of choice for advanced non–small cell lung cancer is selected according to the presence of specific alterations. Patients should undergo molecular testing for relevant modifications and the mutational status of EGFR and translocation of ALK and ROS1 are commonly tested to o...

Descripción completa

Detalles Bibliográficos
Autores principales: Schluckebier, Luciene, Caetano, Rosangela, Garay, Osvaldo Ulises, Montenegro, Giuliana T., Custodio, Marcelo, Aran, Veronica, Gil Ferreira, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489015/
https://www.ncbi.nlm.nih.gov/pubmed/32928143
http://dx.doi.org/10.1186/s12885-020-07240-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489015/
https://www.ncbi.nlm.nih.gov/pubmed/32928143
http://dx.doi.org/10.1186/s12885-020-07240-2

Ejemplares similares